Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

se among AML patients. These data were presented by Ana I. Romero from the Department of Internal Medicine, University of Goteborg in a presentation entitled, "Histamine Dihydrochloride Maintains Cytoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress."

In the study, researchers recovered autoreactive T-cells from AML patients and exposed them to exogenous hydrogen peroxide or oxygen radical-producing mononuclear phagocytes. Ceplene, an inhibitor of oxygen radical formation in phagocytes, completely prevented apoptosis in the T-cell subset (n=8, p<0.0001). In the presence of mononuclear phagocytes, Ceplene synergized with IL-2 in promoting cell cycle proliferation. Based on these findings, researchers concluded that the phenotype of T-cells with spontaneous reactivity against AML blasts is highly sensitive to oxidants and that by inhibiting oxygen radical formation, Ceplene efficiently protects these cytotoxic lymphocytes from apoptosis in an environment of oxidative stress. In addition, Ceplene was shown to synergize with IL-2 to activate and expand these T-cells.

About Ceplene

Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

Ceplene Clinical Trial History

A pivotal Phase III study for Ceplene in conjunction with IL-2 was conducted in 11 countries and included 320 randomized patients. This study met its primary endpoint of preventing relapse as shown by increased LFS at three years for AML patients in remission. The data demonstrated that patients with AML in complete remission who received 18 months of treatment with Ceplene plus low dose IL-2 experienced a significantly improved
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... May 18, 2013 Assisted living ... comes to safety and comfort of their residents. ... provides clients with an effective and cost-efficient solution ... is an integrated, turnkey communications solution that helps ... allowing residents independence and privacy. , The ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... FL (PRWEB) May 18, 2013 The ... to the special places we call home. These are the ... maps. They are the locations where the people are friendly ... show takes viewers off the highways and shares the best ... of both nations with an American sports and film celebrity. ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... 2013 TheBeautyPlace.com answers important questions about ... is not a result of stress, nutrient deficiency or ... Magazine, 70% of men suffer from male patterned baldness. ... renowned for hair transplant surgery, but additionally carries a ... known as Bosley Professional Strength. Their product line is ...
Breaking Medicine News(10 mins):Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3
... The Cosmetic Bootcamp LLC, the leading training ... is pleased to announced reduced tuition scholarships for ... resident in dermatology, plastic surgery, ophthalmology, oculoplastic surgery, ... economic conditions, the sponsors for the meeting have ...
... for millionsBIRMINGHAM, Ala., April 28 As many as 17.8 ... 2050 and 1.57 million will be blind from the disease, ... However, a new medical study by a group of ... University of Alabama Birmingham (UAB) indicates that with ...
... Md. (April 24, 2009) The Henry M. Jackson Foundation ... a one-of-a-kind publication intended to educate anesthesiology residents in ... techniques and acute pain medicine. Its aim is to ... combat trauma. , " The Military Advanced Regional ...
... Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... president and chief executive officer, Hill-Rom. He will be ... New York City on Wednesday, May 13, 2009 at 2 ... via the internet link at http://ir.hill-rom.com/events.cfm ...
... BMP,Sunstone Corporation (Nasdaq: BJGP ) ("BMP Sunstone" ... Baledge to its board of directors following,the Company,s annual ... Mr. Baledge has over two decades ... Mr. Baledge served as Executive Vice President and General,Counsel ...
... Annual Meeting , CHICAGO, April 28 Endo Pharmaceuticals ... clinical trial data in men with hypogonadism who were ... 750 mg) injection, a long-acting testosterone replacement therapy in ... Results showed that average testosterone levels were maintained within ...
Cached Medicine News:Health News:New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement 2Health News:HJF publishes handbook on managing pain of battlefield trauma 2Health News:Hill-Rom to Present at the Bank of America 2009 Health Care Conference 2Health News:BMP Sunstone Appoints Les R. Baledge to Board of Directors 2Health News:Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show 2Health News:Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show 3Health News:Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show 4Health News:Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show 5
(Date:5/16/2013)...  Amgen (NASDAQ: AMGN ) will participate in ... 2013, at the Sheraton New York Times Square in ... Eastern Daylight Time. Joseph P. Miletich , ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/16/2013)... -- OrthoView PSL will allow individual surgeons ... widely-used OrthoView digital templating software via the Cloud and ... started. OrthoView, the leading independent provider of ... dedicated to enabling orthopaedic surgeons in hospitals and private ... film is unavailable. Over 5,000 orthopaedic surgeons in the ...
(Date:5/16/2013)... Developers of a pill bottle that wirelessly transmits ... grand prize winners in the Healthcare Innovation World Cup ... and organized by HITLAB . Winning team ... Langhauser and Mike Morena ... States will receive $50,000 in prize money. They ...
Breaking Medicine Technology:OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 4Wireless Pill Bottle Wins Healthcare Innovation World Cup 5
... CLARA, Calif., March 7, 2011 Samplify Systems, Inc., ... medical, industrial, wireless, and scientific markets, has completed its ... enables the company to fund its rapid growth in ... new markets.  Participating in the round are Integrated Device ...
... plc (Nasdaq: WCRX ) today announced that its ... scheduled to speak at the Goldman Sachs Leveraged Finance Healthcare ... The presentation will be simultaneously webcast at ... available shortly thereafter at http://ir.wcrx.com/events.cfm . ...
Cached Medicine Technology:Samplify Systems Completes Series B Funding 2Samplify Systems Completes Series B Funding 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Plastic Citrate Tube, .109M / 3.2%...
Medicine Products: